🏅 FDA Orphan Designation

OBIZUR

antihemophilic factor (recombinant), porcine sequence

Manufacturer: Takeda Development Center Americas, Inc.

Indicated for:

Rare thrombotic disorder due to a coagulation factors defectOrphanAcquired hemophilia A

FDA-Approved Indications (2)

Rare thrombotic disorder due to a coagulation factors defectOrphan Designation

Treatment of bleeding episodes in adults with acquired hemophilia A.

Acquired hemophilia A

Treatment of bleeding episodes in adults with acquired hemophilia A

Population: adults

Indications & Usage

Treatment of bleeding episodes in adults with acquired hemophilia A.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.